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Abstract. Vitamins play essential roles in cellular reactions
and maintain human health. Recent studies have revealed that
some vitamins including D3, B6 and K2 and their derivatives
have an anti-cancer effect. As a mechanism, their inhibitory
effect on cancer-related angiogenesis has been demonstrated.
Vitamin K2 (menaquinones) has an anti-cancer effect in
particular for hepatic cancer and inhibits angiogenesis. In
the current study, we demonstrated that sole vitamin K3
(menadione) selectively inhibits the in vitro activity of euka-
ryotic DNA polymerase γ, which is a mitochondrial DNA
polymerase, and suppresses angiogenesis in a rat aortic ring
model. The anti-angiogenic effect of vitamin K3 has been
shown in angiogenesis models using human umbilical vein
endothelial cells (HUVECs) with regard to HUVEC growth,
tube formation on reconstituted basement membrane and
chemotaxis. These results suggest that vitamin K3 may be a
potential anti-cancer agent like vitamin K2.
Introduction
The importance of vitamins for human health is well
established. Our research interest has focused on the relation-
ship between vitamins and vascular function, in particularly,
angiogenesis (1). The various functions of vitamin B6 on
endothelial cells, DNA topoisomerase and embryonic stem
cell differentiation (2,3) led us to investigate whether other
vitamins have anti-angiogenic activity. It has been demon-
strated so far that some vitamins, including D3, E and K2,
and their derivatives, have anti-angiogenic activity (4-7). We
have found that vitamin B6 not only inhibits angiogenesis but
also DNA topoisomerase (2), and that anti-angiogenic agents
strongly inhibit DNA polymerase (8,9).
DNA polymerases are indispensable for maintaining the
integrity of the genome, both through faithful replication of
DNA and by repairing damage to DNA. Among the 16 highly
specialized mammalian polymerases, 15 are involved in
maintaining nuclear genetic information (10,11). Replication
and maintenance of the mitochondrial genome relies on a
unique polymerase, DNA polymerase γ (11). DNA polymer-
ase γ is responsible for all aspects of mtDNA synthesis,
including all replication, recombination of the mitochondrial
genome, and repair of mtDNA damage.
Angiogenesis and DNA polymerase are critical targets for
anti-cancer drug development, and an agent inhibiting both
activities would be a potent anti-cancer agent or a good
model for anti-cancer drug design. Thus, we screened low-
molecular weight compounds, which have both anti-angio-
genic and DNA polymerase inhibitory activities. Notably,
vitamin K3, a synthetic vitamin K, showed strong anti-
angiogenic activity and inhibited DNA polymerase γ activity.
In this study, we demonstrated the effects of vitamin K3 on
angiogenesis and DNA polymerase activity.
Materials and methods
Materials. Vitamin K1 (phylloquinone), K2 (menaquinones)
and K3 (menadione) were obtained from Sigma-Aldrich, Inc.
(St. Louis, MO, USA). The chemical structures of vitamin K
compounds are shown in Fig. 1. Nucleotides and chemically
synthesized DNA template-primers such as poly(dA),
poly(rA), and oligo(dT)12-18 and [3H]-dTTP (deoxythymidine
5'-triphosphate, 43 Ci/mmol) were purchased from GE
Healthcare Bio-Sciences (Little Chalfont, Buckinghamshire,
UK). Human recombinant vascular endothelial growth factor
(VEGF) was obtained from R&D Systems (MN, USA). Other
reagents were of special grade as commercially available.
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Enzymes. DNA polymerase α was purified from calf thymus
by immunoaffinity column chromatography as described by
Tamai et al (12). Recombinant rat DNA polymerase ß was
purified from E. coli JMpß5 as described by Date et al (13).
The human DNA polymerase γ catalytic gene was cloned into
pFastBac. Histidine-tagged enzyme was expressed using the
Bac-to-Bac HT Baculovirus Expression System according to
the supplier's instructions (Life Technologies, MD, USA) and
purified using ProBoundresin (Invitrogen Japan, Tokyo,
Japan) (14). Human DNA polymerases δ and ε were purified
by the nuclear fractionation of human peripheral blood cancer
cells (Molt-4) using the second subunit of polymerases δ and
ε-conjugated affinity column chromatography, respectively
(15). Recombinant human DNA polymerases η and ι tagged
with His6 at their C-terminal, were expressed in SF9 insect
cells using the baculovirus expression system, and were
purified as described previously (16,17). A truncated form of
DNA polymerase κ (i.e., hDINB1DC) with 6xHis-tags
attached at the C-terminal, was overproduced using the Bac-
to-Bac Baculovirus Expression System kit (Gibco BRL) and
purified as described previously (18). Recombinant human
His-DNA polymerase λ was overexpressed and purified
according to a method described previously (19). Fish DNA
polymerases α and δ were purified from the testis of cherry
salmon (Oncorhynchus masou) (20). Fruit fly DNA
polymerases α, δ and ε were purified from the early embryos
of Drosophila melanogaster as described previously (21,22).
DNA polymerase α from a higher plant, cauliflower inflores-
cence, was purified according to the methods outlined by
Sakaguchi et al (23). Recombinant rice (Oryza sativa L. cv.
Nipponbare) His-DNA polymerase λ was overexpressed and
purified according to a method described previously (24).
Human immunodeficiency virus type-1 (HIV-1) reverse
transcriptase (recombinant) and the Klenow fragment of DNA
polymerase I from E. coli were purchased from Worthington
Biochemical Corp. (Freehold, NJ, USA). Taq DNA poly-
merase, T4 DNA polymerase, T7 RNA polymerase and T4
polynucleotide kinase were purchased from Takara (Kyoto,
Japan). Calf thymus terminal deoxynucleotidyl transferase
and bovine pancreas deoxyribonuclease I were obtained from
Stratagene Cloning Systems (La Jolla, CA, USA).
DNA polymerase assays. The reaction mixtures for DNA
polymerases α and ß, plant polymerases and prokaryotic
DNA polymerases have been described previously (25,26).
Those for DNA polymerase γ, and polymerases δ and ε were
as described by Umeda et al (14) and Ogawa et al (27),
respectively. The reaction mixtures for DNA polymerases η, ι
and κ were the same as that for polymerase α, and the
reaction mixture for DNA polymerase λ was the same as that
for polymerase α. For DNA polymerases (i.e., DNA-dependent
DNA polymerases), poly(dA)/oligo(dT)12-18 (A/T = 2/1) and
dTTP were used as the DNA template-primer and nucleotide
(i.e., deoxyribonucleotide 5'-triphosphates, dNTP) substrate,
respectively. For HIV-1 reverse transcriptase (i.e., RNA-
dependent DNA polymerase), poly(rA)/oligo(dT)12-18 (A/T =
2/1) and dTTP were used as the template-primer and
nucleotide substrate, respectively. For terminal deoxynucleo-
tidyl transcriptase, oligo(dT)12-18 (3'-OH) and dTTP were
used as the DNA template-primer and nucleotide substrate,
respectively.
Vitamin K compounds were dissolved in distilled dimethyl
sulfoxide (DMSO) at various concentrations and sonicated
for 30 sec. Aliquots of 4 μl of sonicated samples were mixed
with 16 μl of each enzyme (final amount 0.05 units) in 50 mM
Tris-HCl (pH 7.5) containing 1 mM dithiothreitol, 50%
glycerol and 0.1 mM EDTA, and kept at 0˚C for 10 min.
These inhibitor-enzyme mixtures (8 μl) were added to 16 μl
of each of the enzyme standard reaction mixtures, and
incubation was carried out at 37˚C for 60 min, except for Taq
DNA polymerase which was incubated at 74˚C for 60 min.
Activity without the inhibitor was considered 100%, and the
remaining activity at each concentration of the inhibitor was
determined relative to this value. One unit of polymerase
activity was defined as the amount of enzyme that catalyzed
the incorporation of 1 nmol of dNTP (i.e., dTTP) into
synthetic DNA template-primers in 60 min at 37˚C under the
normal reaction conditions for each enzyme (25,26).
Other enzyme assays. The DNA primase activity of DNA
polymerase α, the activities of T7 RNA polymerase, T4 poly-
nucleotide kinase and bovine deoxyribonuclease I were
measured in standard assays according to the manufacturer's
specifications as described by Tamiya-Koizumi et al (28),
Nakayama and Saneyoshi (29), Soltis and Uhlenbeck (30),
and Lu and Sakaguchi (31), respectively.
Ex vivo angiogenesis assay. Male Wistar rats (6 weeks old,
Charles River Laboratories, Kanagawa, Japan) were housed
in metal cages in a room with controlled temperature
(24±1˚C) and a 12-h light/dark cycle (lights on, 08:00-20:00).
They had free access to diets and deionized water. The rats
were maintained according to the ‘Guide for the Care and Use
of Laboratory Animals’ established by Hiroshima University.
The ex vivo angiogenesis assay was performed according to
slightly modified methods as described before (32,33). Briefly,
a male Wistar rat (body weight ~200 g) was sacrificed by
bleeding from the right femoral artery under anesthesia with
diethyl ether. A thoracic aorta was removed and washed with
RPMI-1640 medium (Gibco, New York, USA) to avoid
contamination with blood. It was then turned inside out, and
cut into short segments of about 1-1.5 mm. Collagen gel (gel
matrix solution) was made with 8 volumes of porcine tendon
collagen solution (3 mg/ml) (Cellmatrix Ia, Nitta Gelatin Co.,
Osaka, Japan), 1 volume of 10X Eagle's MEM (Gibco),
1 volume of reconstitution buffer (0.08 M NaOH and 200 mM
HEPES). These solutions were mixed gently at 4˚C. Each
aortic segment was placed in the center of a well on a 6-well
culture plate and covered with 0.5 ml of gel matrix solution
reconstituted as described. The solution was allowed to gel at
37˚C for 20 min. Culture medium [RPMI-1640 medium
containing 1% of ITS+ (Becton Dickinson Labware, MA,
USA)] with various concentration of vitamin K or vehicle
(DMSO) was prepared as described above. The collagen gel
was then overlaid with 2 ml of culture medium. Incubation
was carried out for 10 days in a fully humidified system of
5% CO2 in air at 37˚C. The medium was changed on day 7 of
the culture. An estimation of the length of the capillary was
performed under phase-contrast microscopy by measuring
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the distance from the cut end of the aortic segment to the
approximate mean point of the capillary. Microscopic fields
were photographed with a digital camera (Olympus DSE330-
A System). The length of the capillary was measured using
Adobe Photoshop software. Each reported value represents
the average of culture samples.
Endothelial cells. Human umbilical vein endothelial cells
(HUVECs) were purchased from Kurabo Industries (Osaka,
Japan). Cells were grown in the medium, HuMedia EG-2
(Kurabo Industries, Osaka, Japan), which was modified
MCDB 131 medium containing 2% fetal bovine serum (FBS),
10 ng/ml recombinant human epidermal growth factor (EGF),
1 μg/ml hydrocortisone, 50 μg/ml gentamicin, 50 ng/ml
amphotericin B, 5 ng/ml recombinant human basic fibroblast
growth factor (bFGF) and 10 μg/ml heparin, at 37˚C in
humidified 5% CO2. Subcultures were obtained by treating
the HUVEC cultures with 0.025% trypsin-0.01% EDTA
solution. HUVECs at passage three to seven were used in this
experiment.
HUVEC tube formation assay. Tube formation assay was
performed using BD Matrigel™ (Becton Dickinson and
Company, Tokyo, Japan). Briefly, solid gels were prepared
according to the manufacturer's instructions on a 96-well
tissue culture plate. HUVECs (1x105 cells/ml) in HuMedia
EG-2 medium containing vitamin K3 or vehicle (DMSO)
were seeded 100 μl/well onto the surface of the solid gel, BD
Matrigel. The cells were incubated for 12 h at 37˚C in a CO2
incubator. Tube formation was observed under an inverted
light microscope at 40x magnification. Microscopic fields
were photographed with a digital camera (Olympus DSE330-
A System). The total length of tube structures in each
photograph was measured using Adobe Photoshop software.
Each reported value represents the average of three samples.
HUVEC proliferation assay. For HUVEC proliferation assay,
HUVEC were dispersed with trypsin and suspended in
HuMedia EG-2 medium. A cell suspension (15,000 cells/ml)
was plated onto 96-well culture plates (100 μl/well), and
incubated at 37˚C in a humidified 5% CO2 for 24 h. The
medium was replaced with fresh HuMedia EG-2 containing
vitamin K3. After 72 h, 10 μl of WST-1 reagent was added
into each well of a 96-well plate and incubated for 4 h at
37˚C. The absorbance at 450 nm was measured using a
microplate spectrophotometer
HUVEC chemotaxis assay. This was carried out by a modified
Boyden chamber assay (34). The microporous membranes
(8 μm) of 24-well cell culture inserts (BD Biosciences, MA,
USA) were coated with 0.1% gelatin. HUVECs were detached
with cell dissociation buffer (Invitrogen Corp., Carlsbad, CA,
USA), collected by centrifugation, re-suspended in Medium
199 (Invitrogen) with 0.1% bovine serum albumin (BSA),
and seeded in triplicate in the chamber (1.0x105 cells/400 μl).
The well was filled with 400 μl of Medium 199 containing
0.1% BSA and 10 ng/ml of VEGF with or without vitamin
K3. The assembled chamber was incubated for 6 h at 37˚C in
humidified 5% CO2. Non-migrated cells on the upper surface
of the membrane were removed by scrubbing with a cotton
swab. The cells on the lower surface of the membrane were
fixed with methanol, and stained with Diff-Quik™ stain.
Migrated cells were counted in five fields of each membrane
under a microscope at 200x magnification, and the average
number in a field was calculated. The experiments were
performed in triplicate.
Statistical analysis. Values are presented as means ± SEM.
Data were analyzed by one-way analysis of variance
(ANOVA). Differences of p<0.05 were considered significant.
Results
Effects of vitamin K compounds on DNA polymerase
activities. First, the inhibition of the activities of mammalian
DNA polymerases by vitamin K compounds was investigated
(Fig. 2). In the three vitamin Ks (i.e., K1, K2 and K3) tested,
100 μM of vitamin K3 indicated DNA polymerase γ inhibitory
activity, but the same concentration of vitamins K1 and K2
did not influence the activity of any DNA polymerases tested
including polymerase γ. Vitamin K3 selectively and dose-
dependently inhibited DNA polymerase γ activity, with 50%
inhibition observed at doses of 6.0 μM. DNA polymerase γ is
the sole polymerase in animal mitochondria. Biochemical
and genetic evidence document a key role for polymerase γ
in mitochondrial DNA replication, whereas DNA repair and
recombination were thought to be limited or absent in animal
mitochondria (35). This compound had not influenced the
activities of other mammalian polymerases such as α, ß, δ, ε,
η, ι, κ and λ at all. When activated DNA (i.e., DNA digested
by bovine deoxyribonuclease I) was used as the template-
primer, the mode of inhibition by these compounds did not
change (data not shown). These results suggested that longer
isoprenoid chains of the benzquinone ring in vitamin K
(Fig. 1) weaken the inhibitory effect on DNA polymerase γ.
All vitamin K compounds had no inhibitory effect on fish
(i.e., cherry salmon) DNA polymerases α and δ, insect (i.e.,
fruit fly) polymerases α, δ and ε, plant (i.e., cauliflower and
rice) DNA polymerases α and λ, or prokaryotic DNA polymer-
ases, such as the Klenow fragment of E. coli polymerase I,
Taq DNA polymerase and T4 DNA polymerase (Table I).
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Figure 1. Chemical structures of vitamin K compounds. (A) Vitamin K1, (B)
vitamin K2 and (C) vitamin K3.
A
B
C
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Inhibitory effect of vitamin K compounds on the activities of
other DNA metabolic enzymes. Vitamin K compounds did
not inhibit the activities of other DNA-metabolic enzymes,
such as calf primase of DNA polymerase α, calf terminal
deoxynucleotidyl transferase, HIV-1 reverse transcriptase, T7
RNA polymerase, T4 polynucleotide kinase and bovine
deoxyribonuclease I (Table I). These results may suggest that
vitamin K3 selectively inhibits the activity of mitochondrial
DNA polymerase γ in the polymerases and DNA metabolic
enzymes tested.
We would, however, like to emphasize here that vitamin
K3 at first intercalates into the DNA molecule as the substrate
(i.e., DNA template-primer), and subsequently inhibits both
activities indirectly through the induction of a conformational
change in the DNA. This compound effected no thermal
transition of melting temperature (data not shown), thus, no
vitamin K3 bound to the double stranded DNA, suggesting
that this must inhibit enzyme activities by interacting with
DNA polymerase γ directly. We then investigated whether an
excessive amount of poly(rC) or bovine serum albumin (BSA)
prevented the inhibitory effect of vitamin K3 to determine
whether the effect resulted from their non-specific adhesion
to DNA polymerase γ, or selective binding to specific sites.
Poly(rC) and BSA had little or no influence on the effect of
vitamin K3, suggesting that the binding to DNA polymerase γ
occurs selectively.
Effects of vitamin K compounds on ex vivo angiogenesis. An
anti-angiogenic effect of vitamin K2 has been reported by
Yoshiji et al (7). Thus, we examined the effect of vitamin K
compounds in a rat aortic ring assay. In this angiogenesis assay
model, vitamin K3 also showed strong anti-angiogenic activity
(Fig. 3A). However, vitamin K1 had no inhibitory effect on
angiogenesis (data not shown). Vitamin K3 significantly
inhibited angiogenesis in this model at more than 25 μM
(Fig. 3B)
Effect of vitamin K3 on HUVEC functions. The effect of
vitamin K3 was examined in an in vitro angiogenesis model
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Table I. IC50 values of vitamin K compounds for the activities
of various DNA polymerases and other DNA metabolic
enzymes.
–––––––––––––––––––––––––––––––––––––––––––––––––
Enzyme IC50 values (μM)
–––––––––––––––––––
K1 K2 K3
–––––––––––––––––––––––––––––––––––––––––––––––––
Mammalian DNA polymerases
Calf DNA polymerase α >200 >200 >200
Rat DNA polymerase ß >200 >200 >200
Human DNA polymerase γ >200 >200 6.0±0.3
Human DNA polymerase δ >200 >200 >200
Human DNA polymerase ε >200 >200 >200
Human DNA polymerase η >200 >200 >200
Human DNA polymerase ι >200 >200 >200
Human DNA polymerase κ >200 >200 >200
Human DNA polymerase λ >200 >200 >200
Fish DNA polymerases
Cherry salmon DNA polymerase α >200 >200 >200
Cherry salmon DNA polymerase δ >200 >200 >200
Insect DNA polymerases
Fruit fly DNA polymerase α >200 >200 >200
Fruit fly DNA polymerase δ >200 >200 >200
Fruit fly DNA polymerase ε >200 >200 >200
Plant DNA polymerases
Cauliflower DNA polymerase α >200 >200 >200
Rice DNA polymerase λ >200 >200 >200
Prokayotic DNA polymerases
E. coli DNA polymerase I >200 >200 >200
(Klenow fragment)
Taq DNA polymerase >200 >200 >200
T4 DNA polymerase >200 >200 >200
Other DNA metabolic enzymes
Calf Primase of DNA polymerase α >200 >200 >200
Calf terminal deoxynucleotidyl >200 >200 >200
transferase
HIV-1 Reverse transcriptase >200 >200 >200
T7 RNA polymerase >200 >200 >200
T4 Polynucleotide kinase >200 >200 >200
Bovine deoxyribonuclease I >200 >200 >200
–––––––––––––––––––––––––––––––––––––––––––––––––
These compounds were incubated with each enzyme (0.05 units).
Enzymatic activity was measured as described in Materials and
methods. Enzyme activity in the absence of the compound was
taken as 100%. Data are expressed as the mean ± SEM; n=3.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. Effect of vitamin K compounds on the activities of mammalian
DNA polymerases. Each vitamin K compound (100 μM) was incubated
with each DNA polymerase (0.05 units). The DNA polymerase activities
were measured as described in the text. Enzymatic activity in the absence of
the compound was taken as 100%. Data are expressed as the mean ± SEM
for four independent experiments.
381-387  1/8/08  15:57  Page 384
using HUVECs. HUVECs inoculated on reconstituted base-
ment membrane (Matrigel) migrated, then attached to each
other, and finally formed tube structures (Fig. 4A). Vitamin
K3 suppressed HUVEC tube formation significantly at 25 μM
and completely inhibited it at 50 μM (Fig. 4A and B). This
result was consistent with that in an aortic ring assay.
As many angiogenesis inhibitors suppress endothelial
cell proliferation, we examined the effect of vitamin K3 on
HUVEC proliferation. HUVECs were treated for 72 h with
various concentrations of vitamin K3. Significant differences
(p<0.05) were found between control and vitamin K3-treated
HUVECs (5-25 μM) (Fig. 5).
Finally, the effect of vitamin K3 on HUVEC migration
stimulated with VEGF was examined on gelatin-coated
Boyden chambers. VEGF strongly stimulated HUVEC
migration as shown in Fig. 5. HUVEC migration stimulated
with VEGF was moderately inhibited by vitamin K3 (Fig. 6).
Discussion
Vitamin K3 (menadione) is 2-methyl-1,4-naphthoquinone
and vitamins K1 (phylloquinone) and K2 (menaquinones) are
polyisoprenoid-substituted naphthoquinones. Vitamin K3 is
not found naturally, but is converted to vitamin K2 in vivo.
The functions of these vitamins in cellular reactions are as
well known as those of other vitamins. Vitamin K is a co-
factor of γ-glutamylcarboxylase, which converts glutamic
acid residues of blood coagulation factors and bone matrix
proteins (36,37). Recent studies show that vitamin K2
functions as an anti-cancer agent, in particular, for hepatic
cancer (7,38-41). However, the anti-cancer mechanism of
vitamin K2 on hepatic cancer has not yet been elucidated.
In our study, we demonstrated that vitamin K3 selectively
inhibits DNA polymerase γ and suppresses angiogenesis in
some models. Although an anti-angiogenic effect of vitamin
K2 has been demonstrated (7), an inhibitory effect of vitamin
K3 on DNA polymerase would be a novel finding for vitamin
K compounds. In addition, vitamin K3 selectively inhibits
DNA polymerase γ, which is a mitochondrial DNA poly-
merase. We previously reported that coenzyme Q, which is
an isoprenoid quinine in the mitochondrial respiratory chain,
selectively inhibited both DNA polymerase γ and DNA topo-
isomerase II and suppressed human cancer cell growth (42).
Similarly, vitamin K3 could be useful for cancer treatment or
for the design of a new anti-cancer drug.
As a new function of vitamin K3, we found that it
inhibited angiogenesis. Angiogenesis is a process forming new
blood vessels, and the growth of many solid tumors depends
on it (43). Thus, an anti-angiogenic activity of vitamin K3
inhibiting DNA polymerase γ may contribute to its function
as an anti-cancer agent. In addition, anti-angiogenic activity
of vitamins including D3, B6, K2 and vitamin E derivative
has been reported so far (1,4,7,41,44) and has attracted
attention with regard to cancer prevention and treatment, as
vitamins are relatively safe agents without side effects
compared to anti-cancer drugs. Although vitamin K3 is a
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Figure 3. Effect of vitamin K3 on ex vivo angiogenesis using a rat aortic ring.
(A) Representative result of the inhibitory effect of vitamin K3 (100 μM).
(B) Microvessel length was measured on day 7 of culture. Values are means
± SEM (n=6-12). *Significantly different from control (p<0.01).
Figure 4. Effect of vitamin K3 on HUVEC tube formation on reconstituted
basement membrane. (A) Cells were plated on reconstituted gel and
observed after 12 h. (B) Capillary length was measured, and values are
means ± SEM (n=3). *Significantly different from control (p<0.01).
381-387  1/8/08  15:57  Page 385
synthetic vitamin, it is converted to vitamin K2, which has
anti-angiogenic activity but no effect on DNA polymerase γ
and is used in clinical treatment. Therefore, vitamin K3 could
be used for such a purpose.
We have noted that most of these vitamins and derivative
affect DNA polymerases and angiogenesis (1,2,4-7,44-46),
which led us to consider the usefulness of vitamins inhibiting
both DNA polymerases and angiogenesis to prevent and treat
cancer. Proper consumption of these vitamins could reduce
the risk of cancer.
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